Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Omisirge Market Size And Revenue Outlook Through 2030
The growth witnessed in the past can be linked to the escalating prevalence of hematologic malignancies, the inherent drawbacks of conventional cord blood transplantation, the initial positive results from cell expansion technologies, the increasing utilization of allogeneic stem cell transplants, and the regulatory authorizations for advanced cell therapies.
The projected growth for this period is linked to the development of more personalized cell therapy pipelines, increased investments in regenerative medicine, wider use of advanced transplantation protocols, a stronger commitment to reducing issues after transplantation, and an expansion of the infrastructure for manufacturing cell therapies.
Key trends anticipated during the forecast period involve a greater acceptance of expanded cord blood therapies, increased utilization of ex vivo cell expansion methods, a heightened focus on achieving faster neutrophil engraftment, the broadening of allogeneic hematopoietic stem cell transplantation (HSCT) applications, and improved scalability for cell therapy manufacturing.
Get A Free Sample Report With In-Depth Market Insights:
Omisirge Market Growth Drivers: What’s Behind The Acceleration?
The omisirge market is anticipated to expand due to the rising need for personalized medical interventions. These treatments involve medical approaches customized to an individual’s unique genetic makeup, environmental influences, and lifestyle choices, aiming to maximize efficacy and reduce adverse effects. The surge in demand for such therapies stems from progress in genetic research, a greater understanding of individualized healthcare benefits, and the increasing acknowledgment that bespoke treatments are more effective and have fewer side effects than conventional, generalized methods. Omisirge plays a role in enhancing personalized treatments through its adaptability to individual patient requirements, its capacity to target particular immune reactions, and its optimization of therapeutic results tailored to each patient’s specific cancer characteristics. As an illustration, the Personalized Medicine Coalition, a US-based non-profit, reported in February 2024 that the FDA cleared 16 new personalized treatments for rare disease patients in 2023, marking a considerable rise from the six approvals in 2022. Consequently, the escalating need for personalized treatments is poised to fuel the expansion of the omisirge market.
Omisirge Market Segments: Where Is Growth Concentrated?
The omisirge market covered in this report is segmented –
1) By Clinical Indication: Leukemia, Lymphoma, Myeloma, Other Hematologic Malignancies
2) By Distribution Channel: Direct Sales, Distributors
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers
Omisirge Market Trends: What’s Defining The Industry’s Next Phase?
Major companies in the Omisirge market are emphasizing technological advancements, including omidubicel-onlv, to elevate transplant efficiency and improve patient recovery. Omidubicel-onlv is an allogeneic, stem-cell–based therapy sourced from umbilical cord blood, designed to amplify cell expansion for faster engraftment. For example, in May 2023, the U.S. Food and Drug Administration, a US federal agency, approved Gamida Cell’s product Omisirge, which aims to enhance stem cell engraftment and reduce infection risks for transplant patients. This FDA approval brought forth an improved, expanded cord-blood–derived cell therapy intended to accelerate neutrophil recovery and decrease infection risk in patients suffering from hematologic malignancies. It offers a more consistent engraftment profile than traditional cord blood, facilitating quicker and clinically safer transplants.
Omisirge Market Key Participants And Competitive Landscape
Major companies operating in the omisirge market are Gamida Cell Ltd.
View The Full Omisirge Market Report:
Omisirge Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the omisirge market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omisirge market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model